- Home
- ASRT vs AVTX Comparison
ASRT vs AVTX Comparison
Compare ASRT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- AVTX
- Stock Information
- Founded
- ASRT 1995
- AVTX 2011
- Country
- ASRT United States
- AVTX United States
- Employees
- ASRT N/A
- AVTX N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- AVTX Health Care
- Exchange
- ASRT Nasdaq
- AVTX Nasdaq
- Market Cap
- ASRT 57.9M
- AVTX 57.4M
- IPO Year
- ASRT 1997
- AVTX 2015
- Fundamental
- Price
- ASRT $0.63
- AVTX $4.96
- Analyst Decision
- ASRT Strong Buy
- AVTX Strong Buy
- Analyst Count
- ASRT 2
- AVTX 7
- Target Price
- ASRT $3.25
- AVTX $31.00
- AVG Volume (30 Days)
- ASRT 248.2K
- AVTX 122.3K
- Earning Date
- ASRT 08-06-2025
- AVTX 08-11-2025
- Dividend Yield
- ASRT N/A
- AVTX N/A
- EPS Growth
- ASRT N/A
- AVTX N/A
- EPS
- ASRT N/A
- AVTX N/A
- Revenue
- ASRT $119,001,000.00
- AVTX $441,000.00
- Revenue This Year
- ASRT N/A
- AVTX N/A
- Revenue Next Year
- ASRT $11.91
- AVTX N/A
- P/E Ratio
- ASRT N/A
- AVTX N/A
- Revenue Growth
- ASRT N/A
- AVTX N/A
- 52 Week Low
- ASRT $0.51
- AVTX $3.39
- 52 Week High
- ASRT $1.80
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ASRT 53.64
- AVTX 57.49
- Support Level
- ASRT $0.63
- AVTX $4.76
- Resistance Level
- ASRT $0.68
- AVTX $5.05
- Average True Range (ATR)
- ASRT 0.03
- AVTX 0.30
- MACD
- ASRT 0.00
- AVTX 0.03
- Stochastic Oscillator
- ASRT 74.71
- AVTX 84.75
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).